


Abstract

Pyrrazolo[4,3-d]pyrimidines of the formula I



and their physiologically acceptable salts,

in which

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and X have the meanings indicated in Claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of disorders of the cardiovascular system and for the treatment and/or therapy of potency disorders.